A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects

Trial Profile

A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 19 Apr 2017 Status changed from recruiting to completed.
    • 04 May 2016 Planned number of patients changed from 48 to 64.
    • 04 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top